This gives an overview of a Live Case on the Uppsala Biotech Cluster that I ran in the MBA program at the Stockholm School of Economics in 2005.

1. The Uppsala Biotech Master Case Overview Dr. Robin Teigland, Master Case Facilitator Master of Business Administration Program (MBA) Stockholm School of Economics (SSE) April to June 2005 www.sse.edu/ssemba

4. Countries represented Sweden (25%) United States Latvia Germany Estonia France Japan Iceland Venezuela/Spain Netherlands Denmark India Argentina Turkey Switzerland United Kingdom Greece Total of 36 students Average age: 31 Average no. working years: 6.5 SSE MBA Students – Class of 2005 Educational background

5. Some SSE MBA Students Björn Svensson 43, Sweden Management Consultant Cap Gemini Peter Vriesman 32, Holland Engineer, Electrolux Santosh Nair, India 28, BSc Business Project Manager Patrik Bosander 32, London, MSc KTH Managing Director UK software provider Arwen Schreiber, USA 28, BA, Operations Silicon Valley startups Karin Fisher, 30 Hong Kong, BA, Founder Asian media startup Jeanette Del Valle, 36 Venezuela, BA General Manager Entertainment firm Taavi Lepmets 30, Latvia, Founder LHV, largest investment bank in Baltics Roger Jacobsson, 37 Sweden, Ericsson Business Manager Richard Brorsson, SE 34, MSc Business, Business Development Manager European Commission

10. What is Biotechnology? A group of techniques and technologies that apply the principles of genetics, immunology, and molecular, cellular and structural biology to the discovery and development of novel products – Audretsch 2001

11. What is a Biotechnology Cluster? Biotech firms Other firms, e.g., suppliers, customers Academic and private research organizations Interaction Financing and venture capital firms Government, e.g., policy makers, funding agencies, etc. Support organizations, e.g., patent, consulting & law firms, etc. Enhanced innovation through local interaction

13. Unbroken Tradition of Scientific Achievement in Uppsala Century Scientist Achievement Nobel prize 18th O. Rudbeck The lymphatic system 18th C. Linnæus Systema Naturæ classification 18th A. Celcius Thermometric scale (°C) 18th J.J. Berzelius Chemical elements (Se, Th, Si, Ti, Z) 19th A. J. Ångström Modern spectroscopy (Å unit) 19-20th M. Siegbahn X-ray spectroscopy 19-20th T. Svedberg Ultracentrifuge 20th A. Tiselius Electrophoresis 20th K. Siegbahn Electron spectroscopy 20th J.Porath, P. Flodin Gel filtration 20th G. Johansson, Immunoglobulin E H. Bennich, L. Wide C. Linnæus T. Svedberg A. Tiselius

15. Sponsor Organizations in the Uppsala Biotech Master Case Larger firms: Pharmacia Diagnostics, GE Healthcare Funding agencies, e.g., Vinnova Research organizations, e.g., BMC, Rudbeck, Ångström Interaction Venture capital: HealthCap Smaller organizations: BIO-X , QUIAtech, Resistentia, Svanova Support organizations, e.g., Uppsala Innovation Center, Uppsala BIO, Intersecta Cluster dynamics Sponsor organizations in red

17. Uppsala Biotech MC Sponsor Organizations Year founded in Uppsala No. empl. Company description BIO-X 2004 0 Cross-disciplinary research project with researchers from academia and industry to develop tools for analysis of biomolecules 2000 ~15 Developing tools for genetic analysis, molecular diagnostics, and gene-based therapeutics 1998 ~20 Developing vaccines for treatment of allergies and asthma 2001 ~25 Offering products for diagnosing infectious diseases in livestock 1950s ~600 World leader in blood allergy testing 1940s ~1500 Developing systems & tools for discovery and development of drugs and for manufacture of biopharmaceuticals

19. Uppsala Biotech MC Activities and Supporting Deliverables Phase I Activity: Sponsor Organization Key Issue Deliverable Kick-off Regional Innovation System Presentation Team field visit Field Visit Poster Developing the key issue Key Issue Description Developing key issue recommendations Group Presentation: Key Issue Description & Solution Sketch Uppsala Biotech Day I Presentation of Key Issue Recommendations Delivering value Key Issue Recommendations Final Report Phase II Activity: Nordic Competitiveness in Biotechnology Deliverable Forming an opinion Poster Presentation & Hand-out Presenting an opinion Participation in SSE MBA Symposium

20. Uppsala Biotech MC Deliverables at a Glance Phase I Deliverable: Sponsor Organization Key Issue Due Presented % grade Regional Innovation System Presentation April 20 April 22 -- Field Visit Poster April 25, 13:15 April 25 -- Key Issue Description May 4, 23:59 May 6 10 Group Presentation: Key Issue Description & Solution Sketch May 11, 23:59 May 13 10 Presentation of Recommendation to Sponsor Organization May 27, 23:59 June 3 50 Key Issue Recommendation Final Report June 12, 13:00 N/A Phase II Deliverable: Nordic Competitiveness in Biotechnology Poster Presentation & Hand-out June 28, midnight June 30 30 Participation in Symposium June 30 --

24. The Uppsala Biotech Master Case Kick-off Master of Business Administration Program (MBA) Stockholm School of Economics (SSE) April 22, 2005 Robin Teigland, 070 781 4422 Martin Vidaeus, 070 232 2929

27. Map of Uppsala Bio and Research Labs Uppsala BIO

29. (2) Uppsala Biotech MC Teams Rudbeck Lab Student names in red are team contacts Ångström Lab BMC Lab BIO-X QUIAtech Resistentia Rickard Brorsson Gabriel Catrina Barbara Kraus Jeanette Del Valle Tony Friede Stephan Kuratli Einar Gudmundsson Christine Edman Sebastian Lang Hans Johanssson Sören Holmblad Santosh Nair Alexandrs Pjatibratovs Emil Sunvisson Pontus Nylander Björn Svensson Dheva Raja Evaggelos Sempoglou Pharmacia GE Svanova Håkan Bengtsson Dogan Gegeoglu Erin Donaldson Eriks Ciguzis Patrik Bosander Magnus Fernström Jason Francis Karin Fisher Jerome Panoff Hester Fenwick Peter Vriesman Moritz Wendt Kristine Zelmene Krish Sailam Jun Okamoto Arwen Schreiber Roger Jacobsson Taavi Lepmets

35. The Uppsala Biotech Master Case Phase I Deliverables Master of Business Administration Program (MBA) Stockholm School of Economics (SSE) June 2, 2005

36. Uppsala Biotech MC Sponsor Organizations & Key Issues* BIO-X *Projects have been generalized due to confidentiality aspects. How to ensure research project success? How to commercialize a technology? How to develop a technology more efficiently? How to increase market share in existing products in existing geographical markets? How to enter an existing geographical market with a new product? How to increase profits on existing products in existing markets?

42. The Uppsala Biotech Master Case Biotech Day Master of Business Administration Program (MBA) Stockholm School of Economics (SSE) June 3, 2005

47. Dynamics of Regional Innovation Systems II Course Trip to San Diego, June 18-25, with Prof. M. Walshok Itinerary CO 69 18 June Arlanda-New York, Newark 0925/1210 CO 1426 Newark-San Diego 1735/2023 CO 1827 25 June San Diego-Newark 0800/1628 CO 68 25 June Newark-Arlanda 1800/0755 (26/6) Sun Mon Tue Wed Thu Fri Sat 19 20 21 22 23 24 25 10:00: Orientation to campus and program Overview of campus, city, program resources Walk to beach (optional) Free evening Theme: The Research Base 8:30-11:45 Lectures 12:00 Lunch with life-sci entrepreneur 1:45-2:45 Orientation to projects 3:00-4:30 Tour One: The Research Mesa (possibly on foot) Theme: Knowledge Transfer Mechanisms 8:30-10:00 Lecture 10:15-11:45 CONNECT as a Catalyst for Innovation 12:00 Lunch with CONNECT posterchild 1:45-3:15 (+) Tour Two: Sorrento Valley, North City West, Visit to Qualcomm Theme: Sources of Capital 8:30-10:00 Overview of Funding Sources: VC’s, Angels, Corporate Partners 10:15-11:45 TCA presentation 12:00 Lunch with entrepreneur who has been thro gamut of financing 1:45-3:15 (+) Work on projects Evening (gametime 7:05): Baseball game SD Padres vs. LA Dodgers Theme: Globalization; and Service Sector Infrastructure 8:30-10:00 Globalization of Innovation 10:15-11:45 Lecture on service sector 12:00 Lunch with local entrepreneur or service sector representative 1:45-2:45: Clusters (Mary and Orjan) Remainder of afternoon: work on projects Presentations Morning: completion of projects 12:00: Lunch 1:00-4:30 Student presentations 6:30: Farewell dinner and Midsummer Celebration (Mary’s house) Depart San Diego (8:00am flight)

48. The Final Stretch Uppsala Biotech MC Phase II Deliverables Master of Business Administration Program (MBA) Stockholm School of Economics (SSE) June 24, 2005

55. Symposium on Issues Shaping Nordic Competitiveness in Biotechnology Stockholm School of Economics (SSE) Master of Business Administration Program (MBA) June 30, 2005

58. Issues Shaping Nordic Competitiveness in Biotechnology SSE MBA Inaugural Symposium June 30th, Stockholm School of Economics, Sveavägen 65, Stockholm Stockholm School of Economics Dr. Ketels has led competitiveness projects across the globe, including work on the Massachusetts Biotech Cluster, and is currently conducting an analysis of the competitiveness of the greater Stockholm region with the OECD. Keynote Speaker I Mads Øvlisen Chairman of the Board Novo Nordisk A/S Mads Øvlisen is Chairman of the Board as well as former President and CEO of Novo Nordisk. He is also Chairman of LEGO A/S, the Danish Royal Theatre, and the Wanås Foundation and Adjunct Professor at the Copenhagen Business School. To register (free), contact Helena Kvist-Åslund, helena.aslund@hhs.se, +46 (8) 736-9598 In addition to SSE MBA students, other Session Panelists include: Johan Christenson, Partner, HealthCap Nigel Darby, VP, GE Healthcare Laura Howard, MD, Morgan Stanley, UK Ulf Landegren, Professor, Uppsala Univ. Björn Nilsson, SVP, Biacore Mats Pettersson, CEO, Biovitrum Peter Sellei, VP, Investor AB Ylva Williams, Director, Life Science, ISA Keynote Speaker II Dr. Christian Ketels Head Prof. Porter’s Research Team Institute of Strategy and Competitiveness Harvard Business School

59. SSE MBA Biotech Symposium Time Event Thursday, June 30, 2005 Registration Symposium Welcome Robin Teigland, SSE MBA Session II. The Policy Perspective Nordic Biotech in 2020 – Copying the US or Finding its Own Model? Speaker: Christian Ketels, Harvard Business School Panel Moderator: Robin Teigland, SSE MBA Session I. The Company Perspective How Do We Overcome the Challenges Facing Nordic Biotech Firms? Speaker: Mads Øvlisen, Chairman, Novo Nordisk Panel Moderator: Hans Nyctelius, President, SwedenBIO SSE MBA Poster Session and Coffee Break Symposium Wrap-Up Björn Nilsson, SVP, Biacore; Chairman, SwedenBIO Light Lunch, Mingle, and SSE MBA Poster Session (cont’d) 9:00 - 9:15 8:30 - 9:00 9:15 - 10:30 10:30 - 11:00 11:00 - 12:15 12:15 - 12:30 12:30 - 14:00

61. SESSION I. THE COMPANY PERSPECTIVE Keynote Speaker: Mads Øvlisen Chairman of the Board, Novo Nordisk A/S Mads Øvlisen is former president and CEO of Novo Nordisk and is chairman of several boards: the Danish Royal Theatre, LEGO A/S, and the Wanås Foundation, Sweden. He is also an adjunct professor at the Copenhagen Business School. Moderator: Hans Nyctelius President, SwedenBIO Hans Nyctelius has seventeen years of working experience from the Life Science industry with the last six years in management consultancy at Arthur D. Little and the Boston Consulting Group. He also holds an MBA with distinction from the Warwick Business School (UK). SESSION II. THE POLICY PERSPECTIVE Keynote Speaker: Dr. Christian Ketels Head of Professor Michael Porter’s Research Team Institute of Strategy and Competitiveness Harvard Business School Dr. Ketels has led competitiveness projects across the globe, including work on the Massachusetts Biotech Cluster, and is a member of numerous economic advisory groups in Europe and the Americas. He holds a PhD (Econ) from the London School of Economics. Moderator: Robin Teigland Core Faculty, SSE MBA Robin Teigland’s teaching interests parallel her research interests as she teaches “The Uppsala Biotech Cluster”, a live case that SSE MBA offers its students. She holds a BA (Econ) with distinction from Stanford and an MBA from Wharton, and prior to obtaining her PhD at SSE, she worked as a consultant with McKinsey & Co. For information on the other participants, please see the back. 8:30 – 9:00 9:00 – 9:15 9:15 – 9:30 10:30 – 11:00 11:00 – 12:15 12:15 – 12:30 12:30 – 14:00 Registration Symposium Welcome Robin Teigland, SSE MBA Emil Sunvisson, SSE MBA Session I. The Company Perspective: How Do We Overcome the Challenges Facing Nordic Biotech Firms? Speaker: Mads Øvlisen, Novo Nordisk Moderator : Hans Nyctelius, SwedenBIO Panelists: Nigel Darby, GE Healthcare Laura Howard, Morgan Stanley Ulf Landegren, Uppsala University Mats Pettersson, Biovitrum Krish Sailam, SSE MBA SSE MBA Poster Session & Coffee Break Tony Friede, SSE MBA Session II. The Policy Perspective: Nordic Biotech in 2020 – Copying the US or Finding its Own Model? Speaker : Christian Ketels, HBS Moderator : Robin Teigland, SSE MBA Panelists: Johan Christenson, HealthCap Barbara Kraus, SSE MBA Björn Nilsson, Biacore International Peter Sellei, Investor AB Ylva Williams, Invest in Sweden Agency Symposium Wrap-up Björn Nilsson, Biacore International Light Lunch & SSE MBA Poster Session (cont.) Today’s Program

62. SSE MBA Poster Themes Improving Commercialization of Research How to Choose VC Funding Interested in China for Biotech R&D? M&A Management: A Must for Biotech California 101 – Working within a Californian Biotech Culture Stockholm/Uppsala - A Unified Bio Zone Collaboration for Regional and Global Competitiveness

63. Symposium Write-up in Sweden’s Largest Newspaper